VRTX - Vertex Pharmaceuticals Inc Stock Price, Fair Value and News

422.80USD+3.81 (+0.91%)Delayed

Market Summary

USD422.80+3.81

Delayed

0.91%

VRTX Alerts

2 major insider sales recently.

Big jump in Earnings (Y/Y)

VRTX Stock Price

View Fullscreen

VRTX RSI Chart

VRTX Valuation

Market Cap

108.1B

Price/Earnings (Trailing)

26.9

Price/Sales (Trailing)

10.62

EV/EBITDA

20.03

Price/Free Cashflow

29.09

VRTX Price/Sales (Trailing)

VRTX Profitability

EBT Margin

46.81%

Return on Equity

21.67%

Return on Assets

16.81%

Free Cashflow Yield

3.44%

VRTX Fundamentals

VRTX Revenue

Revenue (TTM)

10.2B

Rev. Growth (Yr)

13.3%

Rev. Growth (Qtr)

6.87%

VRTX Earnings

Earnings (TTM)

4.0B

Earnings Growth (Yr)

57.13%

Earnings Growth (Qtr)

13.5%

Breaking Down VRTX Revenue

52 Week Range

320.01423.25

(Low)(High)

Last 7 days

4.7%

Last 30 days

3.6%

Last 90 days

-0.9%

Trailing 12 Months

19.7%

How does VRTX drawdown profile look like?

VRTX Financial Health

Current Ratio

3.5

VRTX Investor Care

Shares Dilution (1Y)

0.19%

Diluted EPS (TTM)

15.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	10.2B	0	0	0
2023	9.2B	9.5B	9.7B	9.9B
2022	7.9B	8.4B	8.7B	8.9B
2021	6.4B	6.7B	7.1B	7.6B
2020	4.8B	5.4B	6.0B	6.2B
2019	3.3B	3.5B	3.6B	4.2B
2018	2.4B	2.6B	2.8B	3.0B
2017	2.0B	2.1B	2.3B	2.5B
2016	1.3B	1.6B	1.7B	1.7B
2015	600.5M	628.1M	759.0M	1.0B
2014	1.0B	829.7M	787.0M	580.4M
2013	1.4B	1.3B	1.2B	1.2B
2012	1.8B	2.1B	1.8B	1.5B
2011	194.6M	277.4M	912.8M	1.4B
2010	100.3M	112.9M	111.7M	143.4M
2009	157.1M	138.7M	120.3M	101.9M
2008	0	0	0	175.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Vertex Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	bhatia sangeeta n.	sold	-188,178	402	-467	-
May 01, 2024	upadhyay suketu	acquired	-	-	1,001	-
May 01, 2024	upadhyay suketu	back to issuer	-	-	-1,168	-
May 01, 2024	thornberry nancy	acquired	-	-	501	-
May 01, 2024	bhatia sangeeta n.	acquired	-	-	1,001	-
May 01, 2024	carney lloyd	acquired	-	-	1,001	-
May 01, 2024	mckenzie diana	back to issuer	-	-	-1,168	-
May 01, 2024	mckenzie diana	acquired	-	-	1,001	-
Apr 02, 2024	ambrose kristen	sold	-100,560	419	-240	svp & chief accounting officer
Apr 01, 2024	ambrose kristen	sold (taxes)	-94,072	418	-225	svp & chief accounting officer

Which funds bought or sold VRTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	Independent Advisor Alliance	reduced	-2.05	3,574	578,101	0.02%
May 08, 2024	PETTYJOHN, WOOD & WHITE, INC	reduced	-3.23	-2,063	350,711	0.07%
May 08, 2024	Humankind Investments LLC	reduced	-10.42	-73,475	847,724	0.22%
May 08, 2024	Heritage Wealth Advisors	sold off	-100	-7,731	-	-%
May 08, 2024	First National Bank of Hutchinson	added	30.27	244,199	966,022	0.64%
May 08, 2024	GREAT LAKES ADVISORS, LLC	added	133	1,025,840	1,761,490	0.01%
May 08, 2024	J.P. Marvel Investment Advisors, LLC	added	2.77	141,064	2,671,920	0.46%
May 08, 2024	GW&K Investment Management, LLC	reduced	-13.54	-4,000	35,000	-%
May 08, 2024	Russell Investments Group, Ltd.	reduced	-5.06	-2,986,980	115,573,000	0.18%
May 08, 2024	Koshinski Asset Management, Inc.	sold off	-100	-203,445	-	-%

Are Funds Buying or Selling VRTX?

Are funds buying VRTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VRTX

No. of Funds

Unveiling Vertex Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	capital world investors	10.0%	25,902,938	SC 13G/A
Feb 13, 2024	vanguard group inc	8.65%	22,281,729	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	capital world investors	8.6%	22,080,207	SC 13G/A
Jan 25, 2024	blackrock inc.	8.5%	21,881,203	SC 13G
Feb 13, 2023	capital world investors	5.0%	12,939,319	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G
Feb 09, 2023	vanguard group inc	8.39%	21,546,903	SC 13G/A
Jan 24, 2023	blackrock inc.	9.4%	24,241,437	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	2.1%	5,421,291	SC 13G/A

Recent SEC filings of Vertex Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	SC TO-T/A	SC TO-T/A
May 08, 2024	SC TO-T/A	SC TO-T/A
May 07, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading

Peers (Alternatives to Vertex Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.93%	-6.23%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.2B	2.0B	-2.86%	-28.22%	-57.69	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.14%	-14.08%	75.54	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.24%	-16.29%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.09%	107.81%	-9.83	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.77%	-53.41%	-12.37	9.85	394.93%	39.61%
AXSM	3.5B	251.0M	1.40%	-8.18%	-11.81	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-5.68%	-38.85%	-6.52	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.31%	-29.84%	-1.5K	3.09	56.43%	98.83%
SMALL-CAP
CPRX	1.8B	411.3M	-0.76%	-10.51%	28.39	4.49	60.38%	-34.49%
NVAX	627.6M	996.6M	1.36%	-50.17%	-1.57	0.63	-26.66%	65.49%
CRBP	467.4M	881.7K	16.76%	369.92%	-13.85	481.06	-77.61%	33.36%
INO	261.3M	4.9M	-4.04%	14.81%	-1.93	53.69	-54.97%	51.71%
IBIO	6.6M	2.1M	-14.75%	74.53%	-0.24	2.14	-13.45%	66.37%

Vertex Pharmaceuticals Inc News

Latest updates

Vertex Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	6.9%	2,691	2,518	2,484	2,493	2,375	2,303	2,334	2,196	2,098	2,073	1,984	1,793	1,724	1,628	1,538	1,524	1,515	1,413	950	941	858
Costs and Expenses	1.4%	1,551	1,529	1,445	1,467	1,596	1,269	1,208	1,090	1,057	1,195	930	1,831	837	882	866	806	795	862	850	671	582
S&GA Expenses	-7.2%	343	369	264	263	241	267	247	215	215	255	198	195	192	212	185	192	182	195	160	157	147
R&D Expenses	-	-	-	-	-	-	-	-	-	603	694	494	1,407	456	467	493	421	449	480	556	379	339
EBITDA Margin	6.0%	0.49*	0.46*	0.46*	0.46*	0.46*	0.48*	0.47*	0.48*	0.37*	0.37*	0.40*	0.37*	-	-	-	-	-	-	-	-	-
Interest Expenses	194.3%	10.00	-10.60	-10.90	-11.20	-11.40	-11.60	-13.70	-14.60	-14.90	-15.10	-15.20	-15.50	-15.70	16.00	-13.86	-13.87	-14.14	14.00	15.00	15.00	15.00
Income Taxes	0.4%	180	179	144	246	192	258	246	214	193	101	231	-111	168	284	78.00	-12.50	55.00	94.00	13.00	60.00	52.00
Earnings Before Taxes	11.5%	1,279	1,148	1,179	1,162	892	1,077	1,176	1,024	955	871	1,083	-44.20	821	889	746	825	658	677	71.00	327	320
EBT Margin	5.5%	0.47*	0.44*	0.45*	0.45*	0.45*	0.47*	0.46*	0.47*	0.36*	0.36*	0.39*	0.36*	-	-	-	-	-	-	-	-	-
Net Income	13.5%	1,100	969	1,035	916	700	819	931	811	762	770	852	67.00	653	604	667	837	603	583	58.00	267	269
Net Income Margin	7.6%	0.39*	0.37*	0.36*	0.35*	0.35*	0.37*	0.38*	0.38*	0.31*	0.31*	0.31*	0.30*	-	-	-	-	-	-	-	-	-
Free Cashflow	601.5%	1,238	177	1,228	1,075	858	1,045	901	1,087	893	933	875	-249	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	5.2%	23,917	22,730	21,726	20,349	18,974	18,151	16,706	15,582	14,256	13,433	12,619	12,222	12,115	11,752	11,302	10,216	8,893	8,318	7,515	7,033	6,543
Current Assets	-6.0%	13,289	14,144	14,696	13,873	12,966	13,235	12,271	11,504	10,361	9,561	8,853	8,458	8,539	8,133	7,458	6,694	5,446	4,823	4,777	4,711	4,183
Cash Equivalents	-11.7%	9,158	10,369	11,110	10,151	9,290	10,504	9,172	8,702	7,600	6,795	6,276	6,064	6,304	5,988	5,358	4,831	3,593	3,109	3,398	3,295	2,894
Inventory	10.1%	813	739	689	604	535	461	388	368	339	353	333	322	299	281	245	219	187	168	162	143	137
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	921	728	736	745	17.00	731	743
Goodwill	-1.1%	1,088	1,100	1,088	1,088	1,088	1,088	86.00	1,002	1,002	1,002	1,002	1,002	1,002	1,000	1,002	1,002	1,002	1,000	448	50.00	50.00
Liabilities	4.3%	5,371	5,150	5,213	4,879	4,542	4,238	3,677	3,649	3,349	3,333	3,088	3,025	3,135	3,065	3,168	2,697	2,432	2,233	2,261	1,964	1,820
Current Liabilities	7.0%	3,796	3,547	3,599	3,352	3,026	2,742	2,609	2,556	2,180	2,142	1,914	1,836	1,944	1,878	2,004	1,799	1,539	1,335	1,389	1,259	1,106
Shareholder's Equity	5.5%	18,547	17,580	16,513	15,470	14,432	13,913	13,030	11,934	10,907	10,100	9,531	9,196	8,980	8,687	8,133	7,519	6,462	6,085	5,253	5,070	4,723
Retained Earnings	10.8%	11,242	10,142	9,174	8,138	7,223	6,523	5,704	4,773	3,963	3,201	2,431	1,579	1,512	859	254	-412	-1,250	-1,852	-2,436	-2,493	-2,761
Additional Paid-In Capital	-2.2%	7,285	7,450	7,340	7,369	7,220	7,387	7,226	7,100	6,930	6,881	7,086	7,640	7,499	7,894	7,917	7,944	7,696	7,938	7,668	7,564	7,476
Shares Outstanding	0.2%	258	258	258	258	258	257	257	256	255	258	258	259	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	90,700	-	-	-	71,800	-	-	-	51,600	-	-	-	74,800	-	-	-	46,700	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	456.9%	1,307	235	1,268	1,134	900	1,078	956	1,140	956	995	927	-199	921	492	908	1,039	816	446	335	464	325
Share Based Compensation	-8.0%	192	209	131	119	122	112	136	114	130	119	103	105	115	97.00	100	117	116	92.00	85.00	90.00	94.00
Cashflow From Investing	-141.0%	-2,136	-886	-117	-303	-1,833	176	-384	-61.50	-51.00	-134	-52.90	-79.70	-74.30	244	-247	72.00	32.00	-896	-249	-50.19	-39.14
Cashflow From Financing	-198.4%	-357	-119	-165	17.00	-294	40.00	-60.20	48.00	-95.40	-336	-656	34.00	-518	-125	-140	120	-359	161	20.00	-13.01	-41.99
Buy Backs	-5.1%	140	148	123	26.00	133	-	-	-	-	363	642	-	425	131	108	-	300	32.00	12.00	52.00	94.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VRTX Income Statement

2024-03-31

Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Product revenues, net	$ 2,690.6	$ 2,374.8
Costs and expenses:
Cost of sales	342.6	266.9
Research and development expenses	789.1	742.6
Acquired in-process research and development expenses	76.8	347.1
Selling, general and administrative expenses	342.7	241.1
Change in fair value of contingent consideration	(0.1)	(1.9)
Total costs and expenses	1,551.1	1,595.8
Income from operations	1,139.5	779.0
Interest income	181.2	122.6
Interest expense	(10.4)	(11.4)
Other (expense) income, net	(31.2)	1.3
Income before provision for income taxes	1,279.1	891.5
Provision for income taxes	179.5	191.7
Net income	$ 1,099.6	$ 699.8
Net income per common share:
Basic (in dollars per share)	$ 4.26	$ 2.72
Diluted (in dollars per share)	$ 4.21	$ 2.69
Shares used in per share calculations:
Basic (in shares)	258.2	257.4
Diluted (in shares)	261.1	260.3

VRTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 9,158.0	$ 10,369.1
Marketable securities	1,013.3	849.2
Accounts receivable, net	1,793.2	1,563.4
Inventories	813.1	738.8
Prepaid expenses and other current assets	511.1	623.7
Total current assets	13,288.7	14,144.2
Property and equipment, net	1,172.8	1,159.3
Goodwill	1,088.0	1,088.0
Other intangible assets, net	834.9	839.9
Deferred tax assets	1,963.0	1,812.1
Operating lease assets	312.9	293.6
Long-term marketable securities	4,381.4	2,497.8
Other assets	875.7	895.3
Total assets	23,917.4	22,730.2
Current liabilities:
Accounts payable	351.4	364.9
Accrued expenses	2,795.9	2,655.3
Other current liabilities	648.6	527.2
Total current liabilities	3,795.9	3,547.4
Long-term finance lease liabilities	361.5	376.1
Long-term operating lease liabilities	359.8	348.6
Other long-term liabilities	853.6	877.7
Total liabilities	5,370.8	5,149.8
Commitments and contingencies	0.0	0.0
Shareholders’ equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding	0.0	0.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 258,296,249 and 257,695,221 shares issued and outstanding, respectively	2.6	2.6
Additional paid-in capital	7,284.7	7,449.7
Accumulated other comprehensive income (loss)	17.3	(14.3)
Retained earnings	11,242.0	10,142.4
Total shareholders’ equity	18,546.6	17,580.4
Total liabilities and shareholders’ equity	$ 23,917.4	$ 22,730.2

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

CEO	Dr. Reshma Kewalramani FASN, M.D.
WEBSITE	vrtx.com
INDUSTRY	Biotechnology
EMPLOYEES	4800

Vertex Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Vertex Pharmaceuticals Inc? What does VRTX stand for in stocks?

VRTX is the stock ticker symbol of Vertex Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vertex Pharmaceuticals Inc (VRTX)?

As of Thu May 09 2024, market cap of Vertex Pharmaceuticals Inc is 108.13 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VRTX stock?

You can check VRTX's fair value in chart for subscribers.

What is the fair value of VRTX stock?

You can check VRTX's fair value in chart for subscribers. The fair value of Vertex Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vertex Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vertex Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether VRTX is over valued or under valued. Whether Vertex Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Vertex Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VRTX.

What is Vertex Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, VRTX's PE ratio (Price to Earnings) is 26.9 and Price to Sales (PS) ratio is 10.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vertex Pharmaceuticals Inc's stock?

In the past 10 years, Vertex Pharmaceuticals Inc has provided 0.2 (multiply by 100 for percentage) rate of return.